- Home
- G vs EXAS Comparison
G vs EXAS Comparison
Compare G & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- G
- EXAS
- Stock Information
- Founded
- G 1997
- EXAS 1995
- Country
- G Bermuda
- EXAS United States
- Employees
- G N/A
- EXAS N/A
- Industry
- G Professional Services
- EXAS Medical Specialities
- Sector
- G Consumer Discretionary
- EXAS Health Care
- Exchange
- G Nasdaq
- EXAS Nasdaq
- Market Cap
- G N/A
- EXAS 8.8B
- IPO Year
- G 2007
- EXAS N/A
- Fundamental
- Price
- G $50.01
- EXAS $43.66
- Analyst Decision
- G Buy
- EXAS Strong Buy
- Analyst Count
- G 9
- EXAS 18
- Target Price
- G $46.78
- EXAS $70.59
- AVG Volume (30 Days)
- G 1.4M
- EXAS 2.0M
- Earning Date
- G 05-08-2025
- EXAS 05-07-2025
- Dividend Yield
- G 1.36%
- EXAS N/A
- EPS Growth
- G N/A
- EXAS N/A
- EPS
- G 2.85
- EXAS N/A
- Revenue
- G $4,767,139,000.00
- EXAS $2,758,867,000.00
- Revenue This Year
- G $8.91
- EXAS $13.02
- Revenue Next Year
- G $7.47
- EXAS $13.02
- P/E Ratio
- G $17.54
- EXAS N/A
- Revenue Growth
- G 6.48
- EXAS 10.37
- 52 Week Low
- G $30.23
- EXAS $40.62
- 52 Week High
- G $56.76
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- G 45.93
- EXAS 38.22
- Support Level
- G $48.80
- EXAS $44.00
- Resistance Level
- G $51.27
- EXAS $47.23
- Average True Range (ATR)
- G 1.05
- EXAS 1.64
- MACD
- G -0.06
- EXAS 0.17
- Stochastic Oscillator
- G 54.32
- EXAS 30.95
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.